» Articles » PMID: 16021483

Cholinergic Enhancement of Episodic Memory in Healthy Young Adults

Overview
Specialty Pharmacology
Date 2005 Jul 16
PMID 16021483
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Acetylcholine esterase (AchE) inhibitors are known to remediate symptoms of Alzheimer's disease. However, only few systematic data exist on the effects of cholinergic treatment on cognitive functions in normal subjects.

Objective: This study evaluated the effects of donepezil, an inhibitor of AchE, on cognitive performance in young and healthy subjects.

Methods: We used a randomised double-blind parallel group placebo-controlled repeated measures design to investigate changes of cognitive functions in a group of 30 young healthy male subjects (mean age 23.9 years+/-2.24 SD) upon application of donepezil or placebo for 30 days. Attentional and executive functions, visual and verbal short-term and working memory, semantic memory, as well as verbal and visual episodic memory were investigated using an extensive neuropsychological test battery.

Results: Time-by-group interactions demonstrated significant drug effects that were specific to episodic memory in both the verbal and visual domain. Additionally, donezepil significantly improved long-term visual episodic recall. In none of the other functions under investigation any significant treatment effects were observed.

Conclusion: Given this specific drug effect and the well-known relevance of the hippocampal region for episodic memory, we conclude that this region appears to be the major target of cholinergic enhancement in healthy subjects due to long-term inhibition of AchE.

Citing Articles

Neuroenhancement: State of the Art and Future Perspectives.

Marazziti D, Avella M, Ivaldi T, Palermo S, Massa L, Della Vecchia A Clin Neuropsychiatry. 2021; 18(3):137-169.

PMID: 34909030 PMC: 8629054. DOI: 10.36131/cnfioritieditore20210303.


Prevalence and correlates of stimulant and depressant pharmacological cognitive enhancement among Norwegian students.

Myrseth H, Pallesen S, Torsheim T, Erevik E Nordisk Alkohol Nark. 2020; 35(5):372-387.

PMID: 32934539 PMC: 7434145. DOI: 10.1177/1455072518778493.


Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105.

Naughton M, Case L, Peiffer A, Chan M, Stieber V, Moore D Neurooncol Pract. 2018; 5(2):114-121.

PMID: 29770225 PMC: 5946897. DOI: 10.1093/nop/npx016.


'Drugs That Make You Feel Bad'? Remorse-Based Mitigation and Neurointerventions.

Pugh J, Maslen H Crim Law Philos. 2017; 11(3):499-522.

PMID: 29104701 PMC: 5664325. DOI: 10.1007/s11572-015-9383-0.


Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation.

Klaassens B, Rombouts S, Winkler A, van Gorsel H, van der Grond J, van Gerven J Hum Brain Mapp. 2016; 38(1):308-325.

PMID: 27622387 PMC: 5215384. DOI: 10.1002/hbm.23362.


References
1.
Cohen N, Ryan J, Hunt C, Romine L, Wszalek T, Nash C . Hippocampal system and declarative (relational) memory: summarizing the data from functional neuroimaging studies. Hippocampus. 1999; 9(1):83-98. DOI: 10.1002/(SICI)1098-1063(1999)9:1<83::AID-HIPO9>3.0.CO;2-7. View

2.
Gill T, Sarter M, Givens B . Sustained visual attention performance-associated prefrontal neuronal activity: evidence for cholinergic modulation. J Neurosci. 2000; 20(12):4745-57. PMC: 6772472. View

3.
Beglinger L, Gaydos B, Kareken D, Tangphao-Daniels O, Siemers E, Mohs R . Neuropsychological test performance in healthy volunteers before and after donepezil administration. J Psychopharmacol. 2004; 18(1):102-8. DOI: 10.1177/0269881104040248. View

4.
Zihl J, Gron G, Brunnauer A . Cognitive deficits in schizophrenia and affective disorders: evidence for a final common pathway disorder. Acta Psychiatr Scand. 1998; 97(5):351-7. DOI: 10.1111/j.1600-0447.1998.tb10014.x. View

5.
Aigner T . Pharmacology of memory: cholinergic-glutamatergic interactions. Curr Opin Neurobiol. 1995; 5(2):155-60. DOI: 10.1016/0959-4388(95)80021-2. View